Learn about our comprehensive antibody validation methods to ensure monospecificity. Antibody Validation>>

What have we been doing?

Read all the latest news from NeoBiotechnologies.

Leading biotech company launches exclusive license to 10,000 validated antibodies, elevating cancer research efforts worldwide

NeoBiotechnologies Unveils Critical Portfolio of Mouse & Rabbit Monoclonal Antibodies for Cancer Research & Diagnosis

NeoBiotechnologies Receives 2023 Best of Union City Award

Dr. Atul Tandon, Founder of NeoBiotechnologies, named one of the Top 10 Global Leaders from AIIMS Alumni – 2023

NeoBiotechnologies And CDI Laboratories Form Alliance To Distribute CDI’s 2500 Monospecific Transcription Factor Antibodies

Overcoming Resistance to Technological Change

Dr. Atul K. Tandon of NeoBiotechnologies discusses the NLRP3/caspase1/IL-18 signaling pathway in the treatment of eosinophilic esophagitis (EoE)

Ximbio Partnership Helps Expand NeoBiotechnologies’ Hybridoma Collection

Dr. Atul K. Tandon quoted in Pharmaceutical Press’ article on What Techniques Effectively Educate Doctors About New Medications

PARTNERSHIP OPPORTUNITIES

We hold Exclusive rights to 10,000 recombinant and hybridoma antibody products, available for Licensing or Collaboration.

LETS TALK